John Levine – Press/Media — Icahn School of Medicine at Mount Sinai

View Scopus Profile

h-index

Research activity per year

50 - 75 out of 76 results
- Title
- Date(ascending)

Catherine Keays Levine
Levine, J.
23/06/20
1 item of Media coverage
Press/Media
Catherine Keays Levine
Levine, J.
21/06/20
1 item of Media coverage
Press/Media
Kamada Presentation / May 2020
Levine, J.
26/05/20
1 item of Media coverage
Press/Media
Planned Clinical Trial of Allogeneic Stem Cell Therapy Remestemcel-L in Patients with COVID-19
Osman, K., Levine, J. & Gelijns, A.
20/04/20
1 item of Media coverage
Press/Media
Mount Sinai Leading the Way in Innovative Stem Cell Therapy for COVID-19 Patients
Moskowitz, A., Levine, J., Bagiella, E., Osman, K., Gelijns, A. & Iancu-Rubin, C.
10/04/20
1 item of Media coverage
Press/Media
Mount Sinai Leading the Way in Innovative Stem Cell Therapy for COVID-19 Patients
Moskowitz, A., Bagiella, E., Osman, K., Levine, J., Gelijns, A. & Iancu-Rubin, C.
10/04/20
2 items of Media coverage
Press/Media
Mount Sinai Health System Leading the Way in Innovative Stem Cell Therapy for COVID-19 Patients
Moskowitz, A., Bagiella, E., Osman, K., Levine, J., Gelijns, A. & Iancu-Rubin, C.
10/04/20
1 item of Media coverage
Press/Media
Kamada presentation, March 2020
Levine, J.
14/03/20
1 item of Media coverage
Press/Media
Kamada presentation- September 2019
Levine, J.
11/09/19
1 item of Media coverage
Press/Media
Xenikos announces IND clearance by the FDA for a pivotal Phase 3 trial using T-Guard® for treating steroid-refractory acute GVHD
Levine, J.
12/06/19
1 item of Media coverage
Press/Media
Xenikos Announces IND Clearance by the FDA for a Pivotal Phase 3 Trial Using T-Guard(R) for Treating Steroid-refractory Acute GVHD
Levine, J.
12/06/19
1 item of Media coverage
Press/Media
Xenikos Announces IND Clearance by the FDA for a Pivotal Phase 3 Trial Using T-Guard(R) for Treating Steroid-refractory Acute GVHD
Levine, J.
12/06/19
1 item of Media coverage
Press/Media
DGAP-News: Xenikos erhält FDA-Genehmigung zur Durchführung einer pivotalen Phase-3-Studie mit T-Guard(R) zur Behandlung von steroidrefraktärer akuter GVHD
Levine, J.
11/06/19
1 item of Media coverage
Press/Media
Xenikos Announces IND Clearance by the FDA for a Pivotal Phase 3 Trial Using T-Guard(R) for Treating Steroid-refractory Acute GVHD
Levine, J.
11/06/19
1 item of Media coverage
Press/Media
Xenikos Announces IND Clearance by the FDA for a Pivotal Phase 3 Trial Using T-Guard(R) for Treating Steroid-refractory Acute GVHD
Levine, J.
11/06/19
3 items of Media coverage
Press/Media
XENIKOS B : announces IND clearance by the FDA for a pivotal Phase 3 trial using T-Guard(R) for treating steroid-refractory acute GVHD
Levine, J.
11/06/19
1 item of Media coverage
Press/Media
DGAP-News: Xenikos announces IND clearance by the FDA for a pivotal Phase 3 trial using T-Guard(R) for treating steroid-refractory acute GVHD (english)
Levine, J.
11/06/19
1 item of Media coverage
Press/Media
DGAP-News: Xenikos announces IND clearance by the FDA for a pivotal Phase 3 trial using T-Guard(R) for treating steroid-refractory acute GVHD
Levine, J.
11/06/19
1 item of Media coverage
Press/Media
Clinical Challenges: Managing CAR T-Cell Toxicity in Leukemia Patients
Levine, J.
2/06/19
1 item of Media coverage
Press/Media
Clinical Challenges: Managing CAR T-Cell Toxicity in Leukemia Patients
Levine, J.
30/05/19
1 item of Media coverage
Press/Media
Clinical Trial: Itacitinib for Low Risk GVHD
Levine, J.
27/02/19
1 item of Media coverage
Press/Media
Anthony Gismondi: Festival stars make Golden State wines shine
Levine, J.
22/02/19
1 item of Media coverage
Press/Media
Anthony Gismondi: Festival stars make Golden State wines shine
Levine, J.
22/02/19
1 item of Media coverage
Press/Media
Anthony Gismondi: Festival stars make Golden State wines shine
Levine, J.
22/02/19
3 items of Media coverage
Press/Media
Anthony Gismondi: Festival stars make Golden State wines shine
Levine, J.
22/02/19
1 item of Media coverage
Press/Media